SGX trims portfolio to sharpen growth strategy

The sale of Scientific Beta redirects resources towards securities, derivatives, and market data.

Singapore Exchange (SGX) Group has divested its wholly owned subsidiary Scientific Beta as it reallocates capital towards businesses it sees as key to its long-term growth strategy.

The exchange operator said in a media release that the sale reflects its active portfolio management approach, allowing it to redirect resources to capabilities that strengthen its multi-asset franchise.

SGX said it will focus future investments on its securities, derivatives, and data businesses as it sharpens its strategic priorities.

The transaction also positions Scientific Beta for its next stage of growth under its new owner, STOXX Ltd.

SGX said the index provider will be able to expand its research capabilities and global reach following the acquisition.

Despite the sale, SGX will retain its global multi-asset iEdge platform and continue to develop its index business as part of its broader multi-asset offering.

Ng Yao Loong, head of global financial markets at SGX Group, said the divestment enables the company to concentrate on areas with greater long-term growth potential.

"This divestment allows SGX to focus on areas where we see the strongest opportunities to deliver impact for our clients, partners and shareholders, and to further strengthen our multi-asset offering," Ng said.

The divestment comes after SGX took full ownership of Scientific Beta in 2025, following its initial purchase of a 93% stake for $274.76m (€186m) in 2020.

In its first-half FY2026 results, the exchange operator said the unit recorded a net loss of about $15m, including a goodwill impairment, citing recent financial underperformance.

SGX did not disclose the financial terms of the transaction.

($1 = €0.68)